Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial clinical studies with copovithane.

G N Hortobagyi, E M Hersh, N E Papadopoulos

    Journal of Biological Response Modifiers
    |August 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Low-grade inflammation in musculoskeletal disorders: biological basis and role of PRGF].

    Rehabilitacion·2026
    Same author

    Integrating social data and engineering solutions for developing resilient water infrastructure against coastal climate change.

    Scientific reports·2025
    Same author

    Second-order optimization strategies for neural network quantum states.

    Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2024
    Same author

    Nuclear shell-model simulation in digital quantum computers.

    Scientific reports·2023
    Same author

    Is unicentric familial papillary thyroid microcarcinoma different from multicentric?

    Endocrine·2023
    Same author

    Diagnosis and treatment of primary thyroid lymphoma from a surgical perspective: a multi-institutional study.

    Langenbeck's archives of surgery·2023

    Copovithane shows promising antitumor activity in preclinical studies and was well-tolerated in 91 patients with metastatic neoplasms. Further trials are recommended at specific doses.

    Area of Science:

    • Oncology
    • Pharmacology
    • Immunology

    Background:

    • Copovithane is a novel low molecular weight copolymer.
    • Preclinical trials indicated significant in vivo antitumor activity.
    • The mechanism of action for copovithane remains unknown.

    Purpose of the Study:

    • To evaluate the safety and efficacy of copovithane in patients with advanced metastatic neoplasms.
    • To determine optimal dosing for potential future clinical trials.

    Main Methods:

    • Ninety-one patients with metastatic neoplasms received weekly intravenous copovithane.
    • Dose escalation from 1 to 33 g/m2/week was employed.
    • Safety, tolerance, antitumor response, and immunologic parameters were assessed.

    Related Experiment Videos

    Main Results:

    • Copovithane demonstrated excellent tolerance with minimal side effects.
    • Minor responses and partial remissions were observed, primarily in cutaneous and subcutaneous metastases.
    • Intermediate doses showed potential immunomodulatory effects, while higher doses suggested possible immune suppression.

    Conclusions:

    • Copovithane is a well-tolerated agent with some antitumor activity against superficial metastases.
    • Further Phase II clinical trials are warranted at weekly doses of 10-15 g/m2 to confirm efficacy and optimal immunomodulatory effects.